Brain metastasis from prostatic carcinoma

Catane, Raphael; Kaufman, J.; West, Charles; Merrin, Claude; Tsukada, Yoshiaki; Murphy, Gerald P.

doi:10.1002/1097-0142(197612)38:6<2583::aid-cncr2820380652>3.0.co;2-d

Cited by 85 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estimates of the frequency of brain metastasis reported in autopsy series vary from 1% to 6% in patients with a premortem diagnosis of prostate carcinoma, but the true incidence may be 2-10 times greater. [1][2][3][4][5] In this retrospective study of patients with prostate carcinoma, we estimated the incidence of parenchymal CNS metastasis, examining the clinical characteristics and the effects of treatment, histology, location of metastases, and neuroimaging tests on survival.…”

mentioning

confidence: 99%

Brain metastasis from prostate carcinoma

Tremont‐Lukats

Bobustuc

Lagos

et al. 2003

Cancer

202

113

View full text Add to dashboard Cite

Here it goes again: A tandem catalytic process effects sequential Pd0‐catalyzed allylic alkylations through leaving group ionization and PdII‐catalyzed allylic alkylations by CH activation. By employing an oxidative trigger to convert the catalytic species from Pd0 into PdII, both transformations can be conducted in a single reaction vessel using the same precatalyst. This allows for the selective introduction of otherwise indistinguishable allyl groups.

show abstract

mentioning

confidence: 99%

Brain metastasis from prostate carcinoma

Tremont‐Lukats

Bobustuc

Lagos

et al. 2003

Cancer

202

113

View full text Add to dashboard Cite

show abstract

“…Even as the second most common cancer worldwide, prostate cancer rarely metastasizes to the brain, with only 0.2–0.6% of such cases (9,27–29). In general, central nervous system involvement is restricted to the spine, involving the perineural and capsular lymphatic system, as well as Batson's venous plexus (29).…”

Section: Discussionmentioning

confidence: 99%

Suspected tumor-to-meningioma metastasis: A case report

et al. 2017

View full text Add to dashboard Cite

Tumor-to-meningioma metastasis (TMM) is a fairly uncommon phenomenon. Only 7 cases of prostate cancer with TMM have previously been described in the literature. The present study aimed to report a case of prostate cancer TMM, and to discuss the relevant clinical and neuroimaging aspects of this condition. A 68-year-old patient presented with headaches, poor visual acuity in the left eye and ipsilateral eyelid droop 3 years after a Simpson II resection of a left sphenoid wing meningioma. Computed tomography revealed a hyperdense area suggestive of a recurrent left sphenoid wing meningioma. During microsurgical resection of tumor, the tumor presented a fibrous aspect and bled profusely. In the histological examination, a metastatic adenocarcinoma was identified inside the transitional meningioma. The immunohistochemical exam favored a prostatic primary site. The patient died two months later of septic shock from pneumonia. This is a rare metastatic presentation. The pre-operative diagnosis of TMM remains challenging in the majority of cases.

show abstract

“…Most of the data concerning the incidence of brain metastases come from occasional reports or large autopsy series because they were usually asymptomatic in living patients and discovered only incidentally after death [13]. The first retrospective study was published in 1976 by Catane et al, who found an incidence of 4.4% in 91 patients with prostate carcinoma [16]; in 1984, Taylor et al reported that intracranial metastases had been found in 14 out of 126 autopsies (11.1%) performed between 1954 and 1981 [17].…”

Section: Discussionmentioning

confidence: 99%

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era

et al. 2011

View full text Add to dashboard Cite

Central nervous system (brain or leptomeningeal) metastases (BLm) are considered rare in castration-resistant prostate cancer (CRPC) patients. Now that docetaxel has become the reference drug for first-line treatment of CRPC, patients whose disease is not controlled by hormonal manipulations may live much longer than before and have higher risk of developing BLm. We retrospectively reviewed the records of all patients with CRPC attending our centres from 2002 to 2010, and identified all of those who were diagnosed as having BLm and received (or were considered to have been eligible to receive) docetaxel-based treatment. We identified 31 cases of BLm (22 brain metastases and 9 leptomeningeal metastases) with an incidence of 3.3%. BLm-free survival was 43.5 months, and survival after BLm discovery was 4 months. With six patients surviving for more than 1 year after developing BLm, the projected 1-year BL-S rate was 25.8%. The findings of our study may be relevant in clinical practice as they indicate that incidence of BLm in CRPC patients in the docetaxel era seems to be higher than in historical reports, meaning that special attention should be paid to the appearance of neurological symptoms in long-term CRPC survivors because they may be related to BLm.

show abstract

Brain metastasis from prostatic carcinoma

Cited by 85 publications

References 24 publications

Brain metastasis from prostate carcinoma

Brain metastasis from prostate carcinoma

Suspected tumor-to-meningioma metastasis: A case report

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era

Contact Info

Product

Resources

About